Novartis expects to hit the top of its 2018 sales guidance after a strong second quarter, the CEO said, despite joining Pfizer in freezing its U.S. drug prices for the rest of the year following pressure from President Donald Trump.
Reuters: Business News, Reuters: Business
Wed, 07/18/2018 - 3:56am